subcutaneous injection

This randomized clinical trial demonstrates no clinically meaningful difference in pain relief between 20 mg intranasal and subcutaneous ketamine for acute musculoskeletal trauma in the emergency department, with minor adverse events being more common in the subcutaneous group.